Citadel Advisors
VERV

Citadel Advisors’s Verve Therapeutics VERV Stock Holding History

Citadel Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-288,004
Closed -$3.23M – 14205
2025
Q2 		$3.23M Sell
288,004
-23,476
-8% -$134K ﹤0.01% 4850
2025
Q1 		$1.42M Buy
311,480
+182,278
+141% +$1.22M ﹤0.01% 6189
2024
Q4 		$729K Sell
129,202
-615,853
-83% -$3.47M ﹤0.01% 7725
2024
Q3 		$3.61M Buy
745,055
+237,695
+47% +$1.38M ﹤0.01% 4478
2024
Q2 		$2.48M Sell
507,360
-669,725
-57% -$4.21M ﹤0.01% 4916
2024
Q1 		$15.6M Buy
1,177,085
+727,265
+162% +$9.64M ﹤0.01% 2352
2023
Q4 		$6.27M Buy
449,820
+212,617
+90% +$2.64M ﹤0.01% 3487
2023
Q3 		$3.15M Sell
237,203
-458,837
-66% -$7.39M ﹤0.01% 4397
2023
Q2 		$13.1M Buy
696,040
+271,178
+64% +$4.52M ﹤0.01% 2346
2023
Q1 		$6.13M Buy
424,862
+388,028
+1,053% +$7.6M ﹤0.01% 3478
2022
Q4 		$713K Sell
36,834
-33,996
-48% -$901K ﹤0.01% 7504
2022
Q3 		$2.43M Sell
70,830
-1,010,725
-93% -$32.3M ﹤0.01% 5214
2022
Q2 		$16.5M Buy
1,081,555
+101,225
+10% +$1.57M ﹤0.01% 2050
2022
Q1 		$22.4M Buy
980,330
+433,120
+79% +$12.4M ﹤0.01% 1854
2021
Q4 		$20.2M Sell
547,210
-119,174
-18% -$5.01M ﹤0.01% 2008
2021
Q3 		$30.5M Sell
666,384
-163,205
-20% -$9.6M 0.01% 1550
2021
Q2 		$48.7M Buy
+829,589
New +$34.4M 0.01% 1149

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's VERV Position: Q3 2025 in Review

Citadel Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 288,004 shares — an estimated $3.23M sold.

Citadel Advisors first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $48.7M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Citadel Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 288,004 Verve Therapeutics shares in Q3 2025, an estimated $3.23M.
  • Citadel Advisors first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Citadel Advisors's Verve Therapeutics position peaked at $48.7M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.